Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Biogen Investigational Drug Shows Early Promise


 
Photo from the Sept. 1 issue of Nature courtesy of Biogen and the study authors.

Boston-based biotech company Biogen had pre-clinical research and Phase 1b results for aducanumab, its investigational antibody treatment for early Alzheimer's disease, published in the Sept. 1, 2016 issue of Nature.

Information released by Biogen said the pre-clinical animal model and Phase 1b placebo-controlled study in prodromal and mild AD patients (n=165), both demonstrated aducanumab reduced amyloid-beta in the brain and that the reduction was dose-dependent. With the association of amyloid plaque and AD, the hypothesis is that removing the plaque could slow the clinical decline in AD patients. Exploratory results from the Phase 1b study demonstrated dose- and time-dependent slowing of clinical decline as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB) and the Mini-Mental State Examination (MMSE) scores.

"These early studies of aducanumab show its effectiveness in removing amyloid plaque from the brain, as well as its potential effect on the slowing of cognitive decline in patients suffering from Alzheimer's disease," said Alfred Sandrock, MD, PhD, executive vice president and chief medical officer at Biogen.

Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune's technology platform called Reverse Translational Medicine (RTM). Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.

In the Phase 1b study, aducanumab demonstrated acceptable safety and tolerability profiles. The most frequently reported treatment-related serious adverse event and adverse event was ARIA (amyloid-related imaging abnormalities). Two larger Phase 3 trials are currently underway.

 
Share:

Related Articles:


Recent Articles

Tennessee GOP Looks to Pursue Medicaid Block Grant Funding

Tennessee Republican lawmakers have signaled a move to look toward block grant funding as a way to increase access to care for the state's working poor.

Read More

The 2019 Legislative Agenda

A new governor and many new legislators make 2019 a learning year as the state's top healthcare organizations seek to address a number of old issues and tweak some new solutions unveiled last year.

Read More

Updated Cholesterol Guidelines Take a Personalized Approach

The American Heart Association and American College of Cardiology released updated cholesterol clinical guidelines in November 2018, taking a more nuanced approach to care over a patient's lifetime.

Read More

Sharing Data, Saving Lives

In an increasingly connected medical ecosystem where patient safety, health status improvement, and provider reimbursement are impacted at every point along the continuum, the need to efficiently, securely share data appears to have reached a tipping point.

Read More

New Rules in Heart Disease

A number of guideline changes and updates warrant more education around statin use and blood pressure monitoring, but local cardiologists say the higher standards are a game changer.

Read More

Dr. Ashish Shah: A Heart for Transplant Patients

Dr. Ashish Shah is the driving force behind the growth and innovation at one of the nation's busiest heart transplant programs.

Read More

Heart Monitor

Cardiovascular news of note.

Read More

ECMO Program Thriving at TriStar Centennial

A TriStar Centennial, a team approach is key to hospital's successful ECMO program.

Read More

Alexander Looks for Innovation, Asks Council Fellows for Input

Sen. Lamar Alexander asks stakeholders and future leaders to weigh in on ways to improve health outcomes, lower costs.

Read More

CMS Utilizes Dartboard Approach to Modernizing the Medicare Drug Benefit

Controlling pharmaceutical prices remains a hot topic, judging from the 6,415 comments received in response to the CMS proposed rule: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses."

Read More

Email Print
 
 

 

 


Tags:
Aducanumab, Alfred Sandrock, Alzheimer's, Alzheimer's Disease Neuroimaging Initiative, Amyloid Plaque, Biogen, Cognitive Decline
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: